Six-month tier
$199.99/month
Two-month tier
$274.99/month
One-month tier
$299.99/month
Page scope
Shared growth-hormone peptide program
Preparation
Liquid-filled vials described
Testing
IGF-1 testing available; inclusion not established

The starting number belongs to a six-month tier

Maximus displays $199.99 per month for a six-month growth-hormone peptide plan, compared with $274.99 for two months and $299.99 for one month. The page discusses sermorelin and tesamorelin, so the price shown here is a program starting tier rather than a verified individualized sermorelin invoice. Maximus states that dose, plan length and state can affect pricing.

Before comparing this listing with another injection, obtain a quote naming sermorelin and the exact formulation. A shared category page cannot establish that every available prescription costs the same amount.

Commitment and payment timing need separate entries

Six months multiplied by $199.99 totals $1,199.94. Two months at $274.99 totals $549.98. These are arithmetic totals for the displayed periods; neither calculation establishes the payment schedule, financing terms or what happens to an unused balance if treatment stops.

Ask whether the charge is prepaid, collected monthly or paid through a separate financing agreement. Then ask whether ending clinical care cancels remaining financial obligations. A lower monthly equivalent may be attractive, but it should be evaluated alongside the actual commitment and the policy for a clinician-directed change.

The supplied presentation is relatively specific

The page describes liquid-filled vials, injection supplies, alcohol pads and shipping. It also describes a standard vial and a different California presentation, with a 28-day supply reference. These details are useful for asking precise questions, not for calculating your own dose or assuming a fixed quantity applies in every state.

Confirm what your pharmacy will dispense and how a 28-day supply relates to the billing interval. If the amount or formulation changes, ask whether the next shipment, price and intended supply period change together. Keep the dispensing label for any subsequent comparison.

Monitoring is part of the plan to clarify

Maximus emphasizes physician-led care and before-and-after IGF-1 testing through its laboratory service. The public presentation does not establish that every necessary test is included in every tier. Request the price and timing of the initial panel, follow-up testing and clinical review of results.

A laboratory change is not automatically the same as an improvement in the outcome you care about. Ask the clinician which symptoms or functional measures will be followed, how risks will be assessed and what result would prompt a change. A six-month price tier is not a clinical reason to continue an unsuitable therapy.

The boundaries of the comparison

This is a compounded prescription program, not an FDA-approved sermorelin product. The provider's claims about pharmacy testing and natural hormone signaling do not independently establish superior safety or anti-aging benefit. We have not audited its laboratories or treated its testimonials as controlled clinical evidence.

Maximus offers a detailed account of logistics and plan tiers, but the reader still needs a named prescription and full payment terms. Compare it with other injection plans only after those details are settled, and do not transfer tesamorelin claims or approval history to the sermorelin option.

Useful distinctions

  • Multiple duration tiers visible
  • Supplies and shipping described
  • Physician and laboratory pathways described

Limitations to weigh

  • Shared program pricing requires confirmation
  • Six-month starting tier has a larger commitment
  • Laboratory inclusion and refund terms unresolved

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Maximus: Growth Hormone Peptides Provider
  2. FDA: Understanding the Risks of Compounded Drugs Regulatory